[
    {
        "題別": "複",
        "題號": "1",
        "題目": "下列何者是免疫抑制藥物tacrolimus的副作用？",
        "選項": [
            "A. 糖尿病。",
            "B. 腎臟毒性。",
            "C. 高血鉀症。",
            "D. 高血鎂症。",
            "E. 高尿酸症。"
        ],
        "答案": "ABCE",
        "出處": "Morris. Kidney Transplantation, 6th\ned., 2020, chap 17"
    },
    {
        "題別": "複",
        "題號": "2",
        "題目": "有關活體腎臟移植捐贈者的腎切除手術原則，下列何者正 確？",
        "選項": [
            "A. 一般摘取右腎多於左腎。",
            "B. 一般選擇單一腎動脈的一側。",
            "C. 左側腎切除時，腎上腺靜脈須綁緊。",
            "D. 避免拉扯腎動脈。",
            "E. 取輸尿管須儘量清除其周邊組織及血管。"
        ],
        "答案": "BCD",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 27"
    },
    {
        "題別": "複",
        "題號": "3",
        "題目": "有關臨危屍腎捐贈的腎臟移植手術，下列實驗室檢查中那 些是必要的？",
        "選項": [
            "A. ABO血型鑑定。",
            "B. 淋巴球毒殺性交叉試驗（T and B cell cross matching）。",
            "C. 混合淋巴球培養試驗（mixed lymphocyte culture）。",
            "D. Ｂ型肝炎病毒篩檢。",
            "E. 組織符合抗原測定。"
        ],
        "答案": "ABDE",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 27"
    },
    {
        "題別": "複",
        "題號": "4",
        "題目": "有關腎臟移植手術後併發症淋巴囊腫（lymphocele）的敘 述，下列何者正確？",
        "選項": [
            "A. 好發於手術後2-3個月",
            "B. 會導致水腎",
            "C. 會引起頻尿",
            "D. 以空針吸取術為最適當的治療方式",
            "E. 以超音波診斷極不可靠"
        ],
        "答案": "ABC",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 27"
    },
    {
        "題別": "複",
        "題號": "5",
        "題目": "下列那些情況於腎臟移植手術時應考慮切除受贈者原來的 腎臟？",
        "選項": [
            "A. 惡性高血壓",
            "B. 重度貧血",
            "C. 多囊腎過大合併腹部症狀",
            "D. 糖尿病",
            "E. 紅斑性狼瘡"
        ],
        "答案": "AC",
        "出處": "Schwartz's Principle of Surgery, 11th\ned. 2019, chap 11"
    },
    {
        "題別": "複",
        "題號": "6",
        "題目": "一般換腎移植手術組織符合抗原的配對主要考慮六個抗原 包括：",
        "選項": [
            "A. HLA-A 。",
            "B. HLA-B 。",
            "C. HLA-C 。",
            "D. HLA-DR 。",
            "E. HLA-F 。"
        ],
        "答案": "ABD",
        "出處": "Morris. Kidney Transplantation, 6th\ned., 2008, chap 10"
    },
    {
        "題別": "複",
        "題號": "7",
        "題目": "與血液透析治療比較，腎臟移植具有以下那些優點？",
        "選項": [
            "A. 女性患者懷孕成功率增加。",
            "B. 惡性腫瘤機率減少。",
            "C. CMV病毒發病率下降。",
            "D. 飲食較不受限制。",
            "E. 發生糖尿病的機率減少。"
        ],
        "答案": "AD",
        "出處": "Schwartz's Principle of Surgery, 11th\ned. 2019, chap 11"
    },
    {
        "題別": "複",
        "題號": "8",
        "題目": "有關腦死之臨床診斷，下列何者為是？",
        "選項": [
            "A. 必須排除酒精和藥物對中樞神經的影響。",
            "B. 必須排除代謝異常（如：血中鈉離子過高）的影響。",
            "C. 必須排除體溫過低的影響。",
            "D. 腦死病患不可能有spinal reflexes 。",
            "E. 腦死病患不可能有seizures 。"
        ],
        "答案": "ABCE",
        "出處": "Gabriel M, Handbook of Kidney\nTransplantation, 6th ed, 2017. chap 4"
    },
    {
        "題別": "複",
        "題號": "9",
        "題目": "依現行法律、醫學倫理及經驗法則，下列何者不適宜活體 捐贈腎臟？",
        "選項": [
            "A. 年齡16歲。",
            "B. 受腎者的配偶。",
            "C. 腎結石多次病史者。",
            "D. 實際體重大於標準體重50%者。",
            "E. 精神分裂患者。"
        ],
        "答案": "ACDE",
        "出處": "Gabriel M, Handbook of Kidney\nTransplantation, 6th ed, 2017. chap 4"
    },
    {
        "題別": "複",
        "題號": "10",
        "題目": "有關免疫抑制藥物，何者為是？",
        "選項": [
            "A. Cyclosporine與FK506皆是Calcineurin inhibitor且皆具 腎毒性的副作用，二者不合併使用",
            "B. Cyclosporine與Sirolimus皆是Cytochrome P450代謝且 皆具高脂血症的副作用，二者不合併使用",
            "C. 糖尿病是FK506主要的副作用之一",
            "D. 腹瀉及胃腸不適是Myoephenolate Mofetil主要的副作用 之一",
            "E. 腎毒性是Sirolimus主要的副作用之一"
        ],
        "答案": "ACD",
        "出處": "Gabriel M, Handbook of Kidney\nTransplantation, 6th ed, 2017. chap 6"
    },
    {
        "題別": "複",
        "題號": "11",
        "題目": "有關腎臟移植前之評估，下列何者為是？",
        "選項": [
            "A. 抗HLA Class II的IgG antibody是最嚴重的anti-HLA antibody 。",
            "B. Anti-T warm antibody: 1:8（＋）表示有anti-HLA Class II antibody 。",
            "C. Crossmatch之目的在於檢驗是否有preformed anti- donor antibody 。",
            "D. Panel-reactive antibody（PRA）之檢驗值：80%，則 該人不易找到合適的器官捐贈者。",
            "E. IgM antibody通常是auto-antibody，可以忽略不管。"
        ],
        "答案": "CDE",
        "出處": "Gabriel M, Handbook of Kidney\nTransplantation, 6th ed, 2017. chap 8"
    },
    {
        "題別": "複",
        "題號": "12",
        "題目": "有人要捐贈器官。因捐贈者有限，公正公平的器官分配， 在心臟方面必須考慮：",
        "選項": [
            "A. 捐贈者的地理位置不致使缺血時間超長。",
            "B. 接受者病情的嚴重度，使用ECMO者優先。",
            "C. 接受者移植後的益處，存活期長者優先。",
            "D. 接受者政治地位的高低，官高者優先。",
            "E. 捐贈者和接受者ABO血型相配合。"
        ],
        "答案": "ABCE",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "複",
        "題號": "13",
        "題目": "下列那些是屬於同種移植（Allografting）？",
        "選項": [
            "A. 一位亞洲黃種人將心臟捐給陌生的非洲黑人。",
            "B. 一位媽媽將大腿的皮膚捐給三度燒傷的寶貝兒子。",
            "C. 一位老夫子將大腿的大隱靜脈捐做自己冠狀動脈繞道手 術的移植物。",
            "D. 一位B肝衰竭的中國人接受來自非洲之狒狒的肝移植。",
            "E. 一位心肌衰竭的台灣人接受來自非洲之黑猩猩的心臟移 植。"
        ],
        "答案": "AB",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "複",
        "題號": "14",
        "題目": "腎臟移植病人接受活體捐腎（living donor）的好處：",
        "選項": [
            "A. 不必洗腎。",
            "B. 不必苦等屍體捐腎者。",
            "C. 移植後不用吃抗排斥藥。",
            "D. 移植後比來自屍體捐贈者少急性腎衰竭。",
            "E. 移植後長期存活率較高。"
        ],
        "答案": "ABDE",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "複",
        "題號": "15",
        "題目": "移植心臟的冠狀動脈疾病和下列那些有關？",
        "選項": [
            "A. 慢性排斥",
            "B. CMV感染",
            "C. 高血脂症",
            "D. 糖尿病",
            "E. 慢性阻塞性肺疾病"
        ],
        "答案": "ABCD",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 60"
    },
    {
        "題別": "複",
        "題號": "16",
        "題目": "器官移植後的排斥機轉，下列那些敘述正確？",
        "選項": [
            "A. 超急性排斥（hyperacute rejection）由預存抗體（pre- formed autibody）達成",
            "B. 急性排斥（acute rejection）由T淋巴球達成",
            "C. 急性細胞性排斥（acute cellular rejection）由T淋巴球及 巨嗜細胞浸潤達成",
            "D. 急性血管性排斥（acute vascular rejection）因T淋巴球 對異物反應而引起",
            "E. 慢性排斥（chronic rejection）由T和B淋巴球達成"
        ],
        "答案": "ABCDE",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 25"
    },
    {
        "題別": "複",
        "題號": "17",
        "題目": "腎臟移植後發生delayed graft function，下列何者正確？",
        "選項": [
            "A. 須先排除acute vascular or urological complication",
            "B. 可能與donor factor (advancing donor age) 有關",
            "C. 可能與prolonged ischemic time有關",
            "D. 在此期間，可能需要透析治療",
            "E. Acute rejection的機率會增加"
        ],
        "答案": "ABCDE",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 13"
    },
    {
        "題別": "複",
        "題號": "18",
        "題目": "下列何者是環胞靈素（Cyclosporin）的副作用？",
        "選項": [
            "A. Nephrotoxicity",
            "B. Hypertension",
            "C. Neurotoxicity, such as fine hand tremor",
            "D. Hyperuricemia",
            "E. Gingival hyperplasia"
        ],
        "答案": "ABCDE",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 17"
    },
    {
        "題別": "複",
        "題號": "19",
        "題目": "有關移植後糖尿病（posttranplant diabetes）的敘述，何者 為非？",
        "選項": [
            "A. 危險因子包括肥胖、年紀大、糖尿病家族史",
            "B. Corticosteroids、cyclosporine、tacrolimus都是危險因 子",
            "C. 免疫抑制劑減量或停藥並無助於糖尿病控制",
            "D. 腎臟移植後第一年產生糖尿病者約有80﹪",
            "E. 腎臟移植術後，規則監測血糖值是必要的"
        ],
        "答案": "CD",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 14"
    },
    {
        "題別": "複",
        "題號": "20",
        "題目": "有關不適合活體腎臟移植捐贈的敘述，下列何者為正確？",
        "選項": [
            "A. 捐贈者年齡小於18歲或大於70歲",
            "B. Positive T-cell cytotoxic crossmatch",
            "C. Major anatomic disorders of donor kidneys",
            "D. 肝癌病史",
            "E. HIV positive"
        ],
        "答案": "ABCDE",
        "出處": "Gabriel M, Handbook of Kidney\nTransplantation, 6th ed, 2017. chap 7"
    },
    {
        "題別": "複",
        "題號": "21",
        "題目": "有關活體腎臟移植捐贈者的腎切除手術，下列何者為非？",
        "選項": [
            "A. 可以腹腔鏡手術執行",
            "B. 一般摘取右腎多於左腎",
            "C. 輸尿管周邊組織及血管須清除乾淨",
            "D. 單一腎動脈的那一側腎臟優先選擇",
            "E. 腎動脈應避免過度拉扯"
        ],
        "答案": "BC",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 8"
    },
    {
        "題別": "複",
        "題號": "22",
        "題目": "有關活體腎移植的敘述，下列Laparoscopic nephrectomy 的優點？",
        "選項": [
            "A. Less postoperative pain",
            "B. Magnified view of renal vessels",
            "C. Minimal surgical scarring",
            "D. Shorter operative time",
            "E. Shorter hospital stay"
        ],
        "答案": "ABCE",
        "出處": "Gabriel M, Handbook of Kidney\nTransplantation, 6th ed, 2017., chap\n7"
    },
    {
        "題別": "複",
        "題號": "23",
        "題目": "肝臟移植手術（不論屍體捐肝或活體捐肝）時，一定需要 吻合的是哪一個構造？",
        "選項": [
            "A. 肝動脈",
            "B. 肝靜脈",
            "C. 肝門靜脈",
            "D. 下肝靜脈（inferior hepatic vein）<3mm",
            "E. 膽囊管（cystic duct）"
        ],
        "答案": "ABC",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 26"
    },
    {
        "題別": "複",
        "題號": "24",
        "題目": "腎臟移植後兩年，血液中BUN，Creatinine逐漸往上爬升， 下列何者是較為可能之診斷？",
        "選項": [
            "A. 急性排斥",
            "B. 慢性排斥",
            "C. 輸尿管狹窄",
            "D. 抗排斥藥所引起之腎臟毒性",
            "E. 原本之IgA nephropathy再發"
        ],
        "答案": "BCDE",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 27"
    },
    {
        "題別": "複",
        "題號": "25",
        "題目": "在台灣有關活體捐贈實體器官（非骨髓）之規定，下列何 者正確？",
        "選項": [
            "A. 夫妻之間（結婚超過兩年(有小孩者≧1年)）可以互相捐 贈。",
            "B. 兄弟姐妹之間。",
            "C. 朋友之間。",
            "D. 五等姻親之間可以捐贈肝臟。",
            "E. 三等姻親之間可以捐贈腎臟。"
        ],
        "答案": "ABDE",
        "出處": "中華民國人體器官移植條例\n110/01/20"
    },
    {
        "題別": "複",
        "題號": "26",
        "題目": "有關目前所使用之抗排斥藥之作用機轉，下列敘述何者正 確？",
        "選項": [
            "A. cyclosporine是calcineurine 之抑制劑",
            "B. tacrolimus是calcineurine之抑制劑",
            "C. sirolimus是calcineurine之抑制劑",
            "D. basiliximab 是IL-2接受器之阻斷劑",
            "E. mycophenolic acid是白血球DNA合成抑制劑"
        ],
        "答案": "ABDE",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 15-18"
    },
    {
        "題別": "複",
        "題號": "27",
        "題目": "下列何者不是肝臟移植之適應症？",
        "選項": [
            "A. B型肝炎導致之猛爆性肝炎",
            "B. 藥物中毒導致之猛爆性肝炎",
            "C. 肝硬化合併小型肝癌",
            "D. 胰頭癌導致之黃疸及肝衰竭",
            "E. 大腸癌肝臟轉移導致之肝衰竭"
        ],
        "答案": "DE",
        "出處": "Schwartz's Principle of Surgery, 11th\ned. 2019, chap 11"
    },
    {
        "題別": "複",
        "題號": "28",
        "題目": "有關腎臟移植之後的排斥作用，下列敘述何者正確？",
        "選項": [
            "A. 超急性排斥之發生，目前只能預防，幾乎無法治療。",
            "B. 慢性排斥與急性排斥是以發生之時間之早晚來定義。",
            "C. 組織抗原（Human Leukocyte Antigen, HLA）越配合者 越不會發生排斥。",
            "D. 兄弟姐妹間移植即使是組織抗原完全相同也需要使用抗 排斥藥。",
            "E. 移植初期發生多次急性排斥者有較差之腎臟長期存活 率。"
        ],
        "答案": "ACDE",
        "出處": "Morris. Kidney Transplantation, 8th\ned., 2020, chap 25"
    },
    {
        "題別": "複",
        "題號": "29",
        "題目": "從有症狀如黃疸到昏迷的時間很短,稱為猛暴性肝炎(FHF)， 其相關敘述何者為非？",
        "選項": [
            "A. INR＞6.5，Cr＞3.4mg/dL，Age＞40 years 為 poor prognosis factor， 需緊急肝臟移植。",
            "B. 定義FHF必須病患過往無肝炎病史。",
            "C. Non-B，non-C hepatitis virus所引起之FHF較易自我恢 復，不需肝臟移植。",
            "D. 發生黃疸症狀到肝昏迷時間小於七天，較不易自我恢復 ，需緊急肝臟移植。",
            "E. 猛暴性肝炎(FHF)亦可考慮使用acetaminophen 解毒劑 acetylcysteine 。"
        ],
        "答案": "CD",
        "出處": "Schwartz's Principle of Surgery, 11th\ned. 2019, chap 11"
    },
    {
        "題別": "複",
        "題號": "30",
        "題目": "胰臟移植的適應症包括下列何種病人？",
        "選項": [
            "A. 第一型糖尿病合併腎衰竭者。",
            "B. 第二型糖尿病服用口服降血糖藥控制，且合併腎衰竭 者。",
            "C. 第一型糖尿病患者，常合併危害生命的低血糖症。",
            "D. 第一型糖尿病患者，且產生糖尿病合併症。",
            "E. 第二型糖尿病已使用胰島素者且使用胰島素量大於 1.5U/kg/day。"
        ],
        "答案": "ACD",
        "出處": "Hakim, Transplantation Surgery.\n2nd ed, Springer.2021, p205-217"
    },
    {
        "題別": "複",
        "題號": "31",
        "題目": "MELD (model of end stage liver disease) 是評估肝功能及 肝臟疾病死亡率的一個指標。其計算包括那幾項因子？",
        "選項": [
            "A. albumin",
            "B. total bilirubin",
            "C. creatinine",
            "D. K+",
            "E. INR"
        ],
        "答案": "BCE",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 26"
    },
    {
        "題別": "複",
        "題號": "32",
        "題目": "下列那項為肝臟移植之禁忌症？",
        "選項": [
            "A. 肺部aspergillus感染。",
            "B. Ｃ型肝炎感染。",
            "C. 肝癌合併肺轉移。",
            "D. 嚴重hepatopulmonary syndrome 。",
            "E. 部分portal vein non-tumor thrombosis 。"
        ],
        "答案": "ACD",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 26"
    },
    {
        "題別": "複",
        "題號": "33",
        "題目": "肝臟移植手術要吻合的組織包含：",
        "選項": [
            "A. 肝動脈。",
            "B. 肝門脈。",
            "C. 肝靜脈。",
            "D. 膽囊。",
            "E. 肝迷走神經。"
        ],
        "答案": "ABC",
        "出處": "Sabiston Textbook of Surgery: The\nBiological Basis of Modern Surgical\nPractice 21st ed, 2022, Ch26, Page 620"
    },
    {
        "題別": "複",
        "題號": "34",
        "題目": "依據衛生福利部所頒布的等候移植登錄基準，以下那位病 人不適合接受肝臟移植？",
        "選項": [
            "A. 愛滋病患者，最近6個月淋巴免疫細胞指數CD4 = 50 cells/mm3。",
            "B. 第三期乳癌病人，接受根除性治療後滿1年未發現腫瘤 復發。",
            "C. 膽道閉鎖病人，反覆發生膽道感染，周邊血細菌培養為 陰性。",
            "D. 罹患肝癌，腫瘤數量=3；大小分別為3cm、2cm 及1 cm。",
            "E. 酒精性肝硬化，戒酒9個月後，肝功能仍然為Child- Pugh C。"
        ],
        "答案": "AB",
        "出處": "行政院衛生福利部函 /發文日\n期：中華民國壹百零八年六月二\n十四日/發文字號：衛部醫字第\n1081668440A號 難度: 簡單"
    },
    {
        "題別": "複",
        "題號": "35",
        "題目": "腎臟移植前捐贈者與受贈者的組織配對關於HLA(human leukocyte antigen)的配對，下列那些項是目前組織配對的 項目？",
        "選項": [
            "A. HLA-A 。",
            "B. HLA-B 。",
            "C. HLD-C 。",
            "D. HLA-DP 。",
            "E. HLA-DR 。"
        ],
        "答案": "ABE",
        "出處": "Peter J. Morris Kidney\nTransplantation-Principles and\nPractice. 2020, 8th ed, Chapter 10"
    },
    {
        "題別": "複",
        "題號": "36",
        "題目": "有關肝臟移植之等候者及移植者是否接受COVID-19疫苗注 射，下列敘述何者正確？",
        "選項": [
            "A. 肝臟移植等候者最好在移植前2星期以上完成疫苗接 種。",
            "B. 肝臟移植病人移植手術後宜在三個月後接受疫苗接種。",
            "C. 肝臟移植病人因使用抗排斥藥，不必注射COVID-19疫 苗。",
            "D. 肝臟移植病人接受疫苗注射時應暫時減少抗排斥藥。",
            "E. 肝臟移植的捐贈者應接受COVID-19篩檢。"
        ],
        "答案": "ABE",
        "出處": "NIH: COVID-19 treatment\nguidelines. 2022/05/31\nhttps://www.covid19treatmentguideli\nnes.nih.gov/special-\npopulations/transplant/"
    },
    {
        "題別": "複",
        "題號": "37",
        "題目": "心臟移植病患，術後容易發生淋巴癌 (post-transplant lymphoproliferative disorder)，可能與下列何者病毒相關？",
        "選項": [
            "A. Human papilloma virus 。",
            "B. Epstein-Barr virus 。",
            "C. Herpes simplex virus 。",
            "D. Enterovirus 。",
            "E. Cytomegalovirus 。"
        ],
        "答案": "BE",
        "出處": "Cardiac Surgery, Kirklin/Barratt-\nBoyes 4th edition 2013, Part IV\nChapter 21 Page 844"
    },
    {
        "題別": "複",
        "題號": "38",
        "題目": "關於腎臟移植後使用免疫抑制劑副作用，請選出正確敘 述：",
        "選項": [
            "A. Tacrolimus：腎毒性、高血壓、高血糖及高血脂。",
            "B. Mycophenolate mofetil：骨髓抑制、腸胃道不適。",
            "C. Azathioprine：高血糖、高血壓。",
            "D. Sirolimus：高血脂、間質性肺炎。",
            "E. Prednisolone：高血糖、骨質疏鬆、月亮臉。"
        ],
        "答案": "ABDE",
        "出處": "Lenihan, Chapter 72: Clinical\nManagement of the Adult Kidney\nTransplant Recipient, Brenner and\nRector's The Kidney, 10th edition, 2016"
    },
    {
        "題別": "複",
        "題號": "39",
        "題目": "心臟移植後的冠狀動脈疾病和一般沒移植者之冠狀動脈疾 病，通常有些不同，前者：",
        "選項": [
            "A. 往往冗長（diffuse）而非局部。",
            "B. 往往同中心（concentric）而非偏心。",
            "C. 往往因免疫傷害而非單純脂肪堆積。",
            "D. 最後往往需要再移植手術而非一般繞道手術。",
            "E. 往往不會心絞痛。"
        ],
        "答案": "ABCDE",
        "出處": "Sabiston Textbook of Surgery, 21th\ned., 2021. chap 60"
    },
    {
        "題別": "複",
        "題號": "40",
        "題目": "下列那些不是合適的腎臟移植捐贈者？",
        "選項": [
            "A. 一位 37 歲男性 with un-treated HIV died in a traffic accident",
            "B. 一位 80 歲男性 died of septic shock",
            "C. 一位 30 歲男性 died of traumatic ICH",
            "D. 一位 51 歲女性 died of breast CA with brain metastasis",
            "E. 一位 25 歲女性 with SLE nephritis"
        ],
        "答案": "ABDE",
        "出處": "Gabriel M, Handbook of Kidney\nTransplantation, 8th ed, 2017. chap 7"
    },
    {
        "題別": "複",
        "題號": "41",
        "題目": "有關人類組織抗原HLA complex 之敘述，下列何者錯誤？",
        "選項": [
            "A. 主要位於第七對染色體",
            "B. 可以大致區分為classⅠ、Ⅱ",
            "C. ClassⅠ只包括HLA-A和B",
            "D. ClassⅡ包括 HLA-C, DP, DQ, DR",
            "E. 另有 HLA classⅢ其功能尚不清楚。"
        ],
        "答案": "ACD",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 25"
    },
    {
        "題別": "複",
        "題號": "42",
        "題目": "有關器官移植時之組織抗原配對，下列敘述何者不正確？",
        "選項": [
            "A. 常用的檢驗方式為lymphocytotoxicity assay 及 mixed lymphocyte reaction",
            "B. 一般共驗 HLA-A,B,C,DR 等8個allel",
            "C. 在腎臟移植，HLA越相配其5年腎存活率越低",
            "D. 利用genetic-based technique可以驗出各種HLA allel之 種類",
            "E. 在部分器官移植，HLA typing 程度不一定與臨床存活率 有關"
        ],
        "答案": "BC",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 25"
    },
    {
        "題別": "複",
        "題號": "43",
        "題目": "下列那些細胞有參與在器官移植時之急性排斥反應？",
        "選項": [
            "A. macrophage",
            "B. CD4+ T cell",
            "C. CD8+ T cell",
            "D. B cell",
            "E. RBC"
        ],
        "答案": "ABCD",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 25"
    },
    {
        "題別": "複",
        "題號": "44",
        "題目": "有關器官移植時發生的排斥作用，下列敘述何者不正確？",
        "選項": [
            "A. Hyperacute rejection發生於數分鐘至數天",
            "B. Acute rejection 主要是由T cell 之反應所造成",
            "C. Chronic rejection可由B及T cell共同造成",
            "D. Hyperacute rejection 發生時可以立即治療救回植體",
            "E. 急性排斥發生後一般無法救回移植器官"
        ],
        "答案": "DE",
        "出處": "Sabiston Textbook of Surgery, 2021,\ned 21, Chap 25"
    },
    {
        "題別": "複",
        "題號": "45",
        "題目": "有關現行使用的免疫抑制劑作用機轉，下列敘述何者不正 確？",
        "選項": [
            "A. Cyclospprine: 抑制 calcineurin 之作用",
            "B. Tacrolimus: 抑制 calcineurin 之作用",
            "C. Rapamycin: 抑制 IL-2 dependent T-cell proliferation",
            "D. Mycophenolate mofetil: 抑制purine synthesis 然後抑制 所有細胞之分裂及增生",
            "E. Rituximab: 抑制 T-cell 上的CD-28"
        ],
        "答案": "DE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 25"
    },
    {
        "題別": "複",
        "題號": "46",
        "題目": "有關器官移植後之感染症，下列何者不正確？",
        "選項": [
            "A. HBV, HCV, HIV, CMV 均可由移植器官造成接受者感染",
            "B. Pneumocystic pneumonia可以用 trimethoprim- sulfamethoxazole 作術後之預防",
            "C. BK virus 感染一般無害，可以不必太在乎",
            "D. EB virus 和移植後之 PTLD 無關",
            "E. 受贈者本身之黴菌感染有可能在器官移植後活化"
        ],
        "答案": "CD",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 25"
    },
    {
        "題別": "複",
        "題號": "47",
        "題目": "有關抗排斥藥的非免疫性副作用，下列敘述何者正確？",
        "選項": [
            "A. Calcineurin inhibitor 會造成高血壓",
            "B. Tacorlimus 和 steroid 可能造成糖尿病",
            "C. EB 病毒之活化可能造成 PTLD",
            "D. HBV 的活化可能造成 cholestatic sclerosing hepatitis",
            "E. BK virus 可能造成移植腎之腎衰竭"
        ],
        "答案": "ABCDE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 25"
    },
    {
        "題別": "複",
        "題號": "48",
        "題目": "Tolerance 是器官移植醫學的終極目標下列那些方法是有可 能並被用來造成 induced tolerance？",
        "選項": [
            "A. Lymphocyte depletion",
            "B. Co-stimulation blockade",
            "C. chimerism",
            "D. Treg cell and dendritic cell",
            "E. Symchronous bone marrow transplantation"
        ],
        "答案": "ABCDE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 25"
    },
    {
        "題別": "複",
        "題號": "49",
        "題目": "Ｃ型肝炎肝硬化的病人使用DAA (direct acting agent)治療 ，下列敘述何者不正確？",
        "選項": [
            "A. 還是有很高的SVR (sustained viral response)比率",
            "B. 現今因為 HCV 相關疾病需要肝臟移植的人數已明顯減 少",
            "C. Ｃ型肝炎治療達到SVR後即可不必再定期追蹤檢查",
            "D. Ｃ型肝炎病人經治療之後仍然不可以捐贈肝臟",
            "E. Ｃ型肝炎合併輕微肝硬化之病人在治療後肝纖維化仍有 機會改善"
        ],
        "答案": "CD",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 26"
    },
    {
        "題別": "複",
        "題號": "50",
        "題目": "下列何者為肝臟移植之禁忌症？",
        "選項": [
            "A. 嚴重之心血管疾病",
            "B. Portopulmonary hypertension, >50 mmHg",
            "C. 嚴重之hepatopulmonary syndrome",
            "D. Uncontrolled infection",
            "E. 合併有肝外的惡性腫瘤"
        ],
        "答案": "ABCDE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 26"
    },
    {
        "題別": "複",
        "題號": "51",
        "題目": "有關肝臟移植之適應症，下列疾病何者正確？",
        "選項": [
            "A. B型肝炎肝硬化",
            "B. Nonalcoholic fatty liver disease造成之肝硬化",
            "C. Autoimmune hepatitis造成之肝硬化",
            "D. 大腸癌合併肝臟轉移",
            "E. Primary biliary cirrhosis"
        ],
        "答案": "ABCE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 26"
    },
    {
        "題別": "複",
        "題號": "52",
        "題目": "有關小腸移植之適應症，下列狀況何者正確？",
        "選項": [
            "A. 短腸症後群，有合併症",
            "B. 腸道蠕動性疾病",
            "C. 腸道吸收不良症候群",
            "D. Crohn disease 導致之短腸症候群",
            "E. 兒童 NEC (necrotizing enterocolitis) 造成之短腸症候群"
        ],
        "答案": "ABCDE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 28"
    },
    {
        "題別": "複",
        "題號": "53",
        "題目": "下列何者是肝臟移植後發生primary non-function之常見原 因？",
        "選項": [
            "A. 摘取肝臟時之 procurement error",
            "B. High risk donor",
            "C. Fatty liver",
            "D. 抗排斥藥濃度不足",
            "E. 使用 DCD donor (donation after circulatory determination of death)"
        ],
        "答案": "ABCE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 26"
    },
    {
        "題別": "複",
        "題號": "54",
        "題目": "有關活體捐肝肝臟移植之敘述，下列何者正確？",
        "選項": [
            "A. 捐肝者之死亡率約為400至500分之1",
            "B. 至少需留下20%之肝臟給捐肝者",
            "C. 一般希望捐贈肝與受贈者體重之重量比(GRWR)為0.8至 1.0%為安全",
            "D. 大大小小會有約40%之捐肝者會有合併症之發生",
            "E. 脂肪肝、年長者捐肝、高 MELD score 時會希望GRWR (graft recipient weight ratio) 高一些"
        ],
        "答案": "ACDE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 26"
    },
    {
        "題別": "複",
        "題號": "55",
        "題目": "有關腎臟移植之敘述，下列何者不正確？",
        "選項": [
            "A. 以長期存活率來說，腎臟透析比腎臟移植有較好的存率",
            "B. 在美國最常見的腎臟移植疾病是高血壓及糖尿病引起之 腎病",
            "C. FSGS及MPGN type 2 在腎臟移植後很少復發",
            "D. Systemic lupus 在腎移植後很少復發",
            "E. 當 GFR 低於 20ml/min/1.72m2 時即可考慮腎移植，不 一定需要經過透析這ㄧ病程"
        ],
        "答案": "AC",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 27"
    },
    {
        "題別": "複",
        "題號": "56",
        "題目": "HIV (human immunodeficiency virus) 與器官移植之敘述， 下列何者正確？",
        "選項": [
            "A. HIV感染目前仍是腎、肝移植之禁忌症",
            "B. HIV病人治療後仍然可以考慮器官移植",
            "C. HIV病人接受器官移植之條件包括血液 CD4+ 細胞數大 於400/cmm",
            "D. HIV病人接受器官移植之條件包括undetectable viral load",
            "E. HIV(+) 病人可以捐贈器官給 HIV(+) 受贈者"
        ],
        "答案": "BCDE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 27"
    },
    {
        "題別": "複",
        "題號": "57",
        "題目": "下列何者為活體捐腎之禁忌症？",
        "選項": [
            "A. BMI > 40",
            "B. Active malignant disease",
            "C. Horseshoe kidney",
            "D. diabetes",
            "E. Age < 16"
        ],
        "答案": "ABCDE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 27"
    },
    {
        "題別": "複",
        "題號": "58",
        "題目": "在胰臟移植之捐贈者方面，下列敘述何者不正確？",
        "選項": [
            "A. 最好不要有胰臟之 fatty change",
            "B. 胰臟不可以來自 DCD (donation after circulatory death) 捐贈者",
            "C. 理想捐贈者年齡為10-45歲",
            "D. 動脈部分需保留 SMA (superior mesenteric artery) 及 splenic artery",
            "E. 靜脈部分portal vein 保留愈長愈好"
        ],
        "答案": "BE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 27"
    },
    {
        "題別": "複",
        "題號": "59",
        "題目": "胰臟移植時外分泌與內分泌系統之引流，下列敘述何者正 確？",
        "選項": [
            "A. 膀胱外引流的好處是可以即早診斷胰臟之功能及是否有 排斥作用",
            "B. 現今最常使用的仍然是膀胱外引流手術",
            "C. 十二指腸-腸道吻合術比較 physiologic，但有較多合併 症",
            "D.胰臟內分泌系統之 systemic drainage 會造成血液中之胰 島素濃度增加",
            "E. 胰臟內分泌系統之門靜脈引流比較 physiologic ，但是 臨床上沒有明顯優於 sysyemic drainage"
        ],
        "答案": "ADE",
        "出處": "Sabiston Textbook of Surgery, 2022,\ned 21, Chap 27"
    },
    {
        "題別": "複",
        "題號": "60",
        "題目": "有關肝臟移植後評估 graft function 的方法，何者為非？",
        "選項": [
            "A. 需反覆評估 graft 的 function 。",
            "B. 移植術後 hemodynamic stable，病患可以被叫醒，代 表 graft function 好。",
            "C. AST、ALT會在第24小時內上升到最高值，之後逐漸下 降，代表 graft function 好。",
            "D. T型管流出透明 bile juice，且血中 pH 呈現酸性，代表 graft function 好。",
            "E. 動脈血中 pH 值呈現鹼性，代表 graft function 好。"
        ],
        "答案": "CD",
        "出處": "Schwartz's Principle of Surgery, 11th\ned. 2019, chap 11"
    }
]